Combining Irbesartan and Losartan is Not Recommended
Taking both irbesartan and losartan simultaneously is potentially harmful and should not be done. Both medications are angiotensin II receptor blockers (ARBs) that work through the same mechanism, and combining them provides no additional benefit while significantly increasing risks.
Why This Combination is Contraindicated
Guideline-Based Prohibition
The 2017 ACC/AHA Hypertension Guidelines explicitly state that simultaneous use of two ARBs is potentially harmful and is not recommended 1, 2, 3. This represents a Class III: Harm recommendation with Level A evidence 2.
FDA Drug Label Warnings
Both FDA-approved drug labels contain specific warnings against dual RAS (renin-angiotensin system) blockade:
Losartan labeling warns that dual blockade of the RAS with ARBs and ACE inhibitors is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function including acute renal failure 4.
Irbesartan labeling similarly states that dual blockade with two RAS inhibitors is associated with increased risks of hypotension, hyperkalemia, and changes in renal function compared to monotherapy 5.
Clinical Trial Evidence of Harm
The VA NEPHRON-D trial provides definitive evidence against combining RAS inhibitors 4. This study enrolled 1,448 patients with type 2 diabetes and kidney disease, randomizing them to losartan plus lisinopril (an ACE inhibitor) versus losartan alone. Patients receiving the combination experienced increased incidence of hyperkalemia and acute kidney injury without any additional benefit for kidney outcomes or mortality 4.
Specific Risks of Dual ARB Therapy
Combining irbesartan and losartan increases risk for:
- Hyperkalemia (potentially severe elevation in serum potassium) 4, 5
- Hypotension (excessive blood pressure lowering) 4, 5
- Acute kidney injury and worsening renal function 4, 5
- Syncope (fainting episodes) 4
These risks are particularly elevated in patients with:
- Pre-existing chronic kidney disease 4, 5
- Diabetes mellitus 4
- Volume depletion 4
- Concurrent use of potassium supplements or potassium-sparing diuretics 4, 5
What Should Be Done Instead
Immediate Action Required
One of these medications must be discontinued immediately. The choice of which ARB to continue should be based on:
Dose optimization: If one medication is at a suboptimal dose, consider maximizing that single agent first 1, 2, 3
Clinical evidence: Irbesartan has demonstrated superior blood pressure lowering compared to losartan in head-to-head trials 6, 7, 8, with greater reductions in both systolic and diastolic blood pressure 7, 8
Appropriate Combination Strategies
If blood pressure remains uncontrolled on a single ARB at maximum dose, the 2017 ACC/AHA Guidelines recommend adding agents from different drug classes 1, 2, 3:
Preferred combinations with an ARB include:
- ARB + thiazide/thiazide-like diuretic (Grade B) 1, 2, 3
- ARB + dihydropyridine calcium channel blocker (Grade B) 1, 2, 3
- ARB + CCB + thiazide diuretic for three-drug therapy 1, 2, 3
The 2024 ESC Guidelines similarly recommend that combining two RAS blockers (ACE inhibitor and an ARB) is not recommended 9, and this prohibition extends to combining two ARBs.
Monitoring After Discontinuation
After stopping one ARB, monitor:
- Blood pressure response within 1-4 weeks 1, 2
- Serum potassium levels 4, 5
- Renal function (serum creatinine, eGFR) 4, 5
Common Pitfall to Avoid
Do not assume that using two drugs from the same class provides additive benefit. Unlike combining drugs with complementary mechanisms (e.g., ARB + diuretic), combining two ARBs that block the same receptor provides no additional efficacy and only increases adverse effects 1, 2, 10. The 2017 ACC/AHA Guidelines explicitly state that "drug combinations that have similar mechanisms of action or clinical effects should be avoided" 10.